Abstract: Our previous small-scale trial demonstrated an erythropoiesis stimulating agent (ESA)-sparing potential of the TORAYLIGHT NV (NV) dialyzer in hemodialysis patients with high interleukin-6 levels. We now retrospectively explored this ESA-sparing potential of the NV dialyzer in 122 and 129 prevalent dialysis patients who were on the NV and conventional polysulfone (PS) dialyzers, respectively, for 12 months. ESA resistance index (ERI) increased with the PS dialyzers whereas neither ERI nor ESA dose changed with the NV dialyzer. Analyses of baseline ERI or ESA dose-based subgroups revealed a decrease in ERI and ESA dose with the NV dialyzer in patients with a baseline ERI ≥12 IUÁdL/weekÁkgÁg Hb (P < 0.05) and in those with a baseline ESA dose >6000 IU/week (P < 0.001), respectively. Neither ERI nor ESA dose improved in the corresponding subgroups on the PS dialyzers. These findings suggest that NV dialyzer can improve ESA responsiveness in hemodialysis patients with advanced ESA resistance.
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Renal anemia develops in a number of hemodialysis patients. Mainstay treatment is administration of erythropoiesis stimulating agents (ESAs). Some hemodialysis patients become poorly responsive to ESAs and require a higher dose of ESAs than usual to achieve target hemoglobin levels, a condition called ESA resistance. Previous studies indicate that ESA resistance is associated with unfavorable outcomes including cardiovascular disease, early advancement to end-stage renal disease, and death (1) (2) (3) (4) (5) .
The TORAYLIGHT NV dialyzer (NV dialyzer) is equipped with a polysulfone membrane that is modified to enhance the mobility of water adjacent to the membrane (6, 7) . The modifications include local application of a new hydrophilic polymer onto the inner surface of a hollow-fiber membrane composed of polysulfone (6, 7) . This modification reduces dialysis-associated platelet activation that occurs when blood contacts the dialysis membrane (6, 7) . Dialysis with the NV dialyzer appears to improve vascular endothelial function in hemodialysis patients (8) . Recently, it was reported that NV dialyzer has a lower platelet-activating property than that of conventional high-flux dialyzers (9) .
Our previous small-scale randomized controlled trial showed that ESA resistance was improved within 1 year after hemodialysis patients were switched from conventional polysulfone membrane dialyzers onto the NV dialyzer while ESA resistance worsened in those who stayed on conventional polysulfone membrane dialyzers (10) . The trial raised a question whether the observed effect of the NV dialyzer on ESA resistance can be seen in prevalent hemodialysis patients because the trial enrolled 20 patients who were selected for their relatively high serum interleukin-6 levels from 72 eligible patients (10) .
The present study retrospectively analyzed the effect of the NV dialyzer on ESA requirement in a total of 251 prevalent hemodialysis patients.
PATIENTS AND METHODS

Patients and data collection
The study subjects were hemodialysis patients who were treated with polysulfone-type membrane dialyzers for at least 15 consecutive months at 13 participating institutions from October 1, 2012 through March 31, 2015. All participating institutions were private clinics. The patients who were treated for at least 15 consecutive months with conventional polysulfone-type dialyzers (PS dialyzers) alone were grouped in the PS group. Those who were initially treated with PS dialyzers for at least 3 consecutive months and switched onto the NV dialyzer (TORAYLIGHT NV dialyzer, Toray Medical Co., Ltd., Tokyo, Japan), and continued dialysis for at least 12 consecutive months were grouped in the NV group. We set the baseline of data collection at the third month after starting dialysis for the PS group and 1 month before the switch from PS dialyzers to the NV dialyzer for the NV group. The study period was 12 months.
We enrolled those patients who met the inclusion criteria at baseline and did not meet any of the exclusion criteria during the study period. The inclusion criteria were age ≥20 years, at least three sessions of 4 h or longer dialysis session per week, ≥3 months of dialysis vintage with polysulfone membrane dialyzers other than the NV dialyzer, and receiving ESA treatment. The exclusion criteria were treatments for renal failure other than hemodialysis, including peritoneal dialysis, hemodiafiltration, and Lixelle, ESA treatment with epoetin beta pegal, blood infusion, ≥2 weeks of hospitalization, hematological disorders other than renal anemia, being pregnant or having given a birth during the study period, treatments for malignancy in 3 months prior to the baseline or during the study period, or being judged inadequate for the study by principal investigator or participating investigators. Target hemoglobin concentration was 10≤ and <12 g/dL at the first dialysis of the week as recommended in the Japanese Society for Dialysis Therapy guidelines (11) .
Effectiveness of hemodialysis was examined using Kt/V. Dialysate quality was inspected once a month at all participating facilities according to the guidelines of the Japanese Society for Dialysis Therapy (12) . No endotoxin or microorganisms were detected in the dialysates at any time point during the study period.
The following baseline data were collected from the clinical records: age, gender, the date hemodialysis was started, original disease, height, predialysis blood pressure, shunt, and history of cardiovascular disease, bone fracture, malignancy, gastrointestinal bleeding, hepatic disease, or hematological disorder. The following data were collected for every month of the study period: dry weight, predialysis body weight, used dialyzer type, the length of hemodialysis session, Kt/V, membrane surface area, blood flow rate, red blood cell, white blood cell and platelet counts, hemoglobin, albumin, creatinine, calcium, phosphorus, intact parathyroid hormone, iron, transferrin saturation (TSAT), total iron binding capacity (TIBC), ferritin, CRP, ESA type and dose per week, and iron supplementation. Data of ESA type and dose per week were also collected for the 2 months before the baseline month as well as for every month of the study period.
ESA dose and resistance index
The total of ESA dose prescribed in 1 month was averaged for a week, and the resulting mean in IU/week was used as the ESA dose of the month. Darbepoetin alfa dose was converted to ESA dose (IU/week) by multiplying darbepoetin alfa dose prescribed in 1 week (μg) with 200. ESA resistance index (ERI) was derived by dividing the mean weekly ESA dose (IU/week) with dry weight (kg) and hemoglobin concentration (g/dL) and expressed in IUÁdL/weekÁkgÁg Hb (13, 14) .
Statistical analysis
Results were expressed as mean AE SD. ERI and ESA dose were analyzed only in the patients who continued ESA treatment in the 2 months before the baseline month and throughout the study period. For post hoc analyses, ERI and ESA dose of the baseline month and the 2 months before the baseline month were averaged, and the resulting means were used to further divide the patients into three ERI-based or ESA dose-based subgroups: low-ERI <6 IUÁdL/weekÁkgÁg Hb, middle-ERI 6≤ and <12 IUÁdL/weekÁkgÁg Hb, and high-ERI ≥12 IUÁdL/weekÁkgÁg Hb, or low-ESA dose ≤3000 IU/week, middle-ESA dose 3000< and ≤6000 IU/week, and high-ESA dose >6000 IU/ week. These cut-off points were set at the first and third quartile values of baseline ERI and ESA dose of the NV group. The resulting subgroups included the following fractions of the subjects of the NV 
Ethical considerations
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Clinical trials registry
This study is registered with the Clinical Trials Registry of the University Hospital Medical Information Network (registration ID, UMIN 000018431).
RESULTS
Baseline patient characteristics
The NV and PS groups were comparable with the exception of higher age and less frequent history of cardiovascular disease in the NV than in the PS group (Table 1) .
Baseline laboratory data were not significantly different between the groups except hemoglobin concentrations were lower and TIBC was higher in the NV than in the PS group ( Table 2) . As for the conditions of dialysis, Kt/V was not different between the groups. The mean Kt/V was higher than 1.2 in both groups. The membrane area, dialysis time, and blood flow rate were lower in the NV than in the PS group (Table 2) . Baseline ESA dose and ERI were higher in the NV than in the PS group. Iron supplementations were more frequent in the NV than in the PS group (Table 2) . Results are presented as mean AE SD. Shown in parentheses is the range. The numbers shown on the right side of the range and Y/N values are the numbers of patients whose data were available for analysis. DBP, diastolic blood pressure; NV, the NV dialyzer; PS, conventional polysulfone membrane dialyzers; SBP, systolic blood pressure; Y/N, yes/no.
ESA resistance index
ERI was higher in the NV than in PS group at baseline (9.48 AE 5.17 vs. 6.49 AE 3.76 IUÁdL/ weekÁkgÁg Hb; P < 0.001) and month 6 (8.68 AE 6.51 vs. 7.12 AE 5.68 IUÁdL/weekÁkgÁg Hb; P < 0.05), but was not different between the groups at month 12 (8.71 AE 6.05 vs. 7.84 AE 6.59 IUÁdL/weekÁkgÁg Hb; NS) (Fig. 1A) . ERI did not change from the baseline in the NV group throughout the 12-month study period whereas it was significantly higher than the baseline in the PS group at month 12 (P < 0.05; Fig. 1A ).
In order to further characterize the changes in ERI, post hoc analyses were performed after dividing the patients of each group into low-ERI (<6 IUÁdL/weekÁkgÁg Hb), middle-ERI (6≤ and <12 IUÁdL/weekÁkgÁg Hb) and high-ERI (≥12 IUÁdL/weekÁkgÁg Hb) subgroups according to the baseline ERI.
There were 28 and 68 low-ERI patients in the NV and PS groups, respectively (Fig. 1B ). ERI were significantly higher in the low-ERI patients of the NV than in those of the PS group at baseline (4.45 AE There were 69 and 50 middle-ERI patients in the NV and PS groups, respectively (Fig. 1C) . ERI was not different between the middle-ERI patients of the NV and PS groups at baseline (8.52 AE 1.74 vs. 8.24 AE 1.79 IUÁdL/weekÁkgÁg Hb; NS), but was significantly lower at month 12 in the NV group than the PS group (8.24 AE 5.15 vs. 10.69 AE 6.68 IUÁdL/weekÁkgÁg Hb; P < 0.05). ERI did not change from the baseline in the NV group throughout the study period, but was significantly higher than the baseline at month 12 in the PS group (8.24 AE 1.79 vs. 10.69 AE 6.68 IUÁdL/weekÁkgÁg Hb; P < 0.05; Fig. 1C ).
There were 25 and 11 high-ERI patients in the NV and PS groups, respectively (Fig. 1D) (Fig. 1D) . However, ERI was significantly lower than the baseline in the NV group at month Results are presented as mean AE SD. Shown in parentheses is the range. The numbers shown on the right side of the range and Y/N values are the numbers of patients whose data were available for analysis. Ca, calcium; Cr, creatinine; CRP, C-reactive protein; ESA, erythropoiesis stimulating agent; ERI, ESA resistance index, Fe, iron; inPTH, intact parathyroid hormone; iP, inorganic phosphate; NV, the NV dialyzer; PLT, platelet; PS, conventional polysulfone membrane dialyzers; RBC, red blood cell; TIBC, total iron binding capacity; TSAT, transferrin saturation; UN, urea nitrogen; WBC: white blood cell; Y/N, yes/no. 12 (17.75 AE 4.60 vs. 13.36 AE 7.52 IUÁdL/weekÁkgÁg Hb; P < 0.05). ERI did not change significantly in the PS group.
The overall changes that occurred in ERI during the 12-month study period (ΔERI) are shown in Figure 2. At the study population level, the overall changes were −0.77 AE 5.93 IUÁdL/weekÁkgÁg Hb in the NV group and 1.35 AE 5.71 IUÁdL/weekÁkgÁg Hb in the PS group (Fig. 2A) . The difference between the groups was significant (P < 0.05). Post hoc analysis of the patient subgroups revealed a significant difference in the overall change in the middle-ERI patients of the NS and PS groups (−0.28 AE 5.34 vs. 2.45 AE 6.39 IUÁdL/weekÁkgÁg Hb; P < 0.05) (Fig. 2C) . The overall changes were not different between the NS and PS groups in the low-ERI patients (1.26 AE 3.80 vs. 0.96 AE 3.66 IUÁdL/weekÁkgÁg Hb; NS) ( Fig. 2A) (Fig. 2D) .
ESA dose
ESA dose was higher in the NV than in the PS group at baseline (5052 AE 2239 vs. 3657 AE 1720 U/ week; P < 0.001) and month 6 (4557 AE 2921 vs. 3882 AE 2407 U/week; P < 0.05) (Fig. 3A) . However, ESA dose was not different between the NV and PS groups at month 12 (4594 AE 279 vs. 4213 AE 2924 U/week). ESA dose did not change significantly in either the NV or PS group during the study period.
In order to further characterize the changes in ESA dose, post hoc analyses were performed after dividing the patients of each group into low-ESA dose (≤3000 IU/week), middle-ESA dose (3000< and ≤6000 IU/week) or high-ESA dose (>6000 IU/week) subgroups according to the baseline ESA dose.
There were 21 and 61 low-ESA patients in the NV and the PS groups, respectively (Fig. 3B) . ESA dose was not significantly different between the low-ESA patients of the NV and PS groups throughout the study period. ESA dose did not change significantly from the baseline in the NV group during the study period (baseline, 2393 AE 462 IU/week; month 6, 3196 AE 2224 IU/week; and month 12, 2900 AE 2051 IU/week). In contrast, ESA dose was higher than the baseline in the PS group at month 6 (2292 AE 622 vs. 3080 AE 2102 IU/week; P < 0.01) and month 12 (3151 AE 2370 IU/week; P < 0.01).
There were 67 and 54 middle-ESA patients in the NV and the PS groups, respectively (Fig. 3C) . ESA dose did not change significantly from the baseline in the middle-ERI patients of the NV group (baseline, 4349 AE 755 IU/week; month 6, 4092 AE 2388 IU/ week; and month 12, 4647 AE 2421 IU/week) or in those of the PS group (baseline, 4296 AE 799 IU/ There were 34 and 14 high-ESA patients in the NV and the PS groups, respectively (Fig. 3D) . ESA dose was higher in the high-ERI patients of the NV group than in those of the PS group at baseline (8082 AE 1468 vs. 7140 AE 1108 IU/week; P < 0.01). However, ESA dose was not different between the NV and PS groups at month 6 (6316 AE 3476 vs. 6152 AE 3475 IU/week) and month 12 (5538 AE 3410 vs. 7231 AE 3679 IU/week). ESA dose was significantly lower than the baseline (8082 AE 1468 IU/ week) in the NV group at month 6 (6316 AE 3476 IU/week; P < 0.01) and month 12 (5538 AE 3410 IU/week; P < 0.001). ESA dose did not change significantly from the baseline in the PS group during the study period.
The overall changes that occurred in ESA dose during the 12-month study period (ΔESA dose) are shown in Figure 4 . At the study population level, the overall changes were −458 AE 3058 IU/week in the NV group and 556 AE 2564 IU/week in the PS group (Fig. 4A) . The difference between the groups was significant (P < 0.01). Post hoc analysis of the patient subgroups revealed a significant difference between the high-ESA dose patients of the NV and PS groups (−2543 AE 3724 vs. 91 AE 3680 IU/week; P < 0.05) (Fig. 4D) . No significant differences were found between the NV and PS groups in the low-ESA dose patients (507 AE 1948 vs. 859 AE 2252 IU/ week) (Fig. 4B) or the middle-ESA dose patients (298 AE 2437 vs. 334 AE 2570 IU/week) (Fig. 4C ).
Hemoglobin
Hemoglobin concentrations were lower in the NV than in the PS group at baseline (P < 0.001), but were not different between the groups at month 12. Hemoglobin concentrations did not change from the baseline in the NV group throughout the study period, but were lower than the baseline in the PS group at month 6 (P < 0.05) and 12 (P < 0.05).
For the low-ERI patients, hemoglobin concentrations were lower in the NV than in the PS group at baseline (P < 0.01), but were not different between the groups at months 6 or 12. Hemoglobin concentrations did not change from the baseline in the NV group throughout the study period, but were lower than the baseline in the PS group at months 6 (P < 0.01) and 12 (P < 0.01). For the middle-ERI patients, hemoglobin concentrations were lower in the NV than in the PS group at baseline (P < 0.05), but were not different between the groups at months 6 or 12. For the high-ERI patients, hemoglobin concentrations neither were different between the groups nor changed in either group.
C-reactive protein CRP was not different between the NV and PS groups or between the corresponding ERI-based subgroups throughout the study period, and did not change significantly in either the NV or PS group, or in any of the subgroups.
Iron utilization
TSAT was lower in the NV group than in the PS group at baseline (P < 0.01) and month 6 (P < 0.01), but was not different between the groups at month 12 (Table 3) . TSAT did not change in either group throughout the study period. For the low-ERI patients, TSAT did not change in the NV group but was lower than the baseline in the PS group at month 12 (P < 0.05). For the middle-ERI patients, TSAT neither was different between the groups nor showed significant changes from the baseline in either group. For the high-ERI patients, TSAT was not different at baseline between the groups but was lower in the NV group than in the PS group at month 12 (P < 0.05). TSAT did not change significantly from the baseline in either group.
The frequency of iron supplementations was significantly higher in the NV than in the PS group at baseline and month 6 (Table 3) . Prescribed iron supplementations were all intravenous.
Laboratory data
White blood cell and platelet counts were not different at baseline between the NV and PS groups or between corresponding ERI-based subgroups, and did not change significantly in either group or any subgroup throughout the study period (Table 3) .
Serum albumin was not different between the NV and PS groups or between the corresponding ERIbased subgroups throughout the study period, and did not change significantly in either the NV or PS group, or in any of the subgroups (Table 3) .
DISCUSSION
ERI and ESA dose were higher in the NV than in PS group at baseline and month 6, but were not different between the groups at month 12. The overall changes in ERI and ESA dose were both reductions in the NV group compared to those in the PS group. Subgroup analyses revealed a significant decrease in ERI and ESA dose in the high-ERI and high-ESA patients, respectively, of the NV group. In contrast, ERI increased in the low-and middle-ERI patients, and ESA dose increased in the low- ESA patients of the PS group. Thus, ESA responsiveness improved in the highly ESA-resistant patients of the NV group. ESA resistance either remained unchanged or worsened in the subgroups of the PS group.
Hemoglobin did not change in the NV group or in any of its ERI-based subgroups whereas a significant decrease occurred in the PS group and its low-ERI patients. TSAT did not change in either the NV or PS group or in their ERI-based subgroups except it decreased in the low-ERI patients of the PS group. CRP and serum albumin did not change significantly in either the NV or PS group, or in any of the subgroups throughout the study period. Taken together, ESA resistance was improved in the high-ERI patients of the NV group with no changes in hemoglobin, TSAT, CRP, or albumin. In contrast, ESA resistance worsened in the low-ERI patients of the PS group in association with decreases in hemoglobin and TSAT and no changes in CRP or albumin.
Our previous small-scale randomized controlled trial showed that ESA dose and ERI decreased in hemodialysis patients within 1 year after the patients were switched from conventional PS dialyzers onto the NV dialyzer (10) . The mean baseline ESA dose of the subjects was 3050 AE 2147 IU/ week, which would place these patients in the lowor middle-ESA dose subgroup of the present study. These patients have similarities and differences with the present high-ERI patients. The inclusion and exclusion criteria were essentially identical between the two studies except baseline dialysis vintage was ≥7 years as opposed to ≥15 months in the present study, resulting in the baseline vintage of 18.0 AE 6.9 years in the previous patients and 8.7 AE 7.2 years in the present high-ERI patients. Importantly, the previous patients were enrolled for their relatively high baseline serum interleukin-6 (IL-6) levels (mean AE SD 5.4 AE 2.1 pg/mL; range 3.2-8.5 pg/mL) in the initial population of 72 eligible patients. This selection was done because the primary objective of the trial was to compare dialysis-associated IL-6 removal and induction between the NV and conventional PS dialyzers (10) . The baseline CRP was 1.48 AE 1.52 (range 0.26-5.25) μg/mL as opposed to 0.38 AE 1.19 (range 0.01-6.00) mg/dL in the present high-ERI patients. Other baseline values of the previous patients and present high-ERI patients, respectively, are hemoglobin 11.1 AE 1.1 vs. 9.8 AE 0.7 g/dL and age 57 AE 11 vs. 67 AE 10 years. Given that the present study was powered for analyses at 
